HLA-I and breast cancer prognosis: A systematic review and meta-analysis.

Autor: Cezar Aquino de Moraes F; Federal University of Pará, Belem, Pará, 66073-005, Brazil. Electronic address: francisco.cezar2205@gmail.com., Henrique Cavalcanti Orestes Cardoso J; University of Pernambuco, Recife 50100-130, Brazil., Alves Kelly F; Dante Pazzanese Institute of Cardiology, São Paulo, São Paulo, 04012-909,Brazil., Kreuz M; Lutheran University of Brazil, Canoas, RS, 92425-900, Brazil., Rodrigues Fernandes L; AFYA Faculty of Medical Sciences, Abaetetuba, Pará, 68440-000, Brazil., Cristina Figueroa Magalhães M; Mackenzie Evangelical University Hospital, Curitiba, Paraná, 80730-150, Brazil., Mario Rodríguez Burbano R; Ophir Loyola Hospital, Belém, Pará, 66063-240, Brazil.
Jazyk: angličtina
Zdroj: Human immunology [Hum Immunol] 2024 Nov; Vol. 85 (6), pp. 111148. Date of Electronic Publication: 2024 Sep 24.
DOI: 10.1016/j.humimm.2024.111148
Abstrakt: Background: Breast cancer (BC) is a significant global health issue, accounting for 1 in 8 cancer diagnoses worldwide. HLA class I molecules are typically expressed on the cell surface, but cancer cells can develop mechanisms to evade recognition by CTLs, including the downregulation of HLA class I expression. In this context, we aimed to conduct a systematic review and meta-analysis to clarify the role of HLA class I expression in clinical outcomes for patients with BC.
Methods: A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and the Cochrane databases. Effect sizes, along with I 2 and Tau 2 statistics, were used to assess heterogeneity through a DerSimonian and Laird random-effects model. Statistical analyses were performed using R statistical software, version 4.2.3.
Results: Among the 8 included studies, most of the analyzed samples consisted of ductal carcinoma cases (1588, 86.39 %), from the luminal (A or B) intrinsic subtype (1865, 69.07 %), with no lymph node metastasis (2658, 57.24 %), no HER2 overexpression (2594, 67.46 %), negative Ki67 status (1721, 71.26 %), and positive hormone receptor status (4732, 64.05 %). The analysis revealed a significant reduction in disease-free survival (HR 0.57; 95 % CI 0.34 to 0.95; p = 0.034; I 2  = 84 %) in the group with low HLA-I expression. However, no significant difference was found between the groups with high and low HLA-I expression regarding overall survival (HR 0.77; 95 % CI 0.28 to 2.14; p = 0.62; I 2  = 86 %).
Conclusions: This systematic review and meta-analysis demonstrated that HLA class I expression is associated with a significant improvement in disease-free survival, though no significant effect on overall survival was observed.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: